Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11

Huperzine A for vascular dementia. Cochrane Database Syst Rev (2009) 0.90

Oxidative modulation of voltage-gated potassium channels. Antioxid Redox Signal (2013) 0.89

Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacology (2011) 0.86

Screening for cognitive decline following single known stroke using the Mini-Mental State Examination. Neuropsychiatr Dis Treat (2011) 0.82

Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: a pilot study. Pediatr Blood Cancer (2012) 0.81

[Validation of indicators of the management of cognitive impairment in geriatric assessment units]. Can Fam Physician (2007) 0.77

Genetics of Vascular Dementia. Minerva Psichiatr (2010) 0.75

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21

Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74

Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39

Alzheimer's disease. Lancet (2011) 5.35

Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 5.05

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66

Vascular cognitive impairment. Lancet Neurol (2003) 3.73

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48

Dementia with Lewy bodies. Lancet Neurol (2004) 2.66

Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol (2009) 1.86

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc (2003) 1.83

Dissection of cervical arteries: Long-term follow-up study of 130 consecutive cases. Cerebrovasc Dis (2006) 1.60

Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults: evidence from a cognitive intervention program. Dement Geriatr Cogn Disord (2006) 1.57

Training-related brain plasticity in subjects at risk of developing Alzheimer's disease. Brain (2011) 1.56

Pharmacotherapy of Alzheimer disease. Can J Psychiatry (2007) 1.43

Should physicians prescribe cognitive enhancers to healthy individuals? CMAJ (2012) 1.41

Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Int Psychogeriatr (2008) 1.39

Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther (2010) 1.30

Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ (2008) 1.21

Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke (2004) 1.17

Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PLoS One (2008) 1.17

Cognitive complaint in mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc (2008) 1.16

Early-onset familial Alzheimer's disease (EOFAD). Can J Neurol Sci (2012) 1.12

Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychology (2007) 1.11

Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimers Dement (2010) 1.11

Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol (2010) 1.07

Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res (2007) 1.05

Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis (2009) 1.04

The concept of vascular cognitive impairment. Front Neurol Neurosci (2009) 1.03

Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol (2011) 1.02

Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry (2005) 1.01

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci (2011) 1.01

REM sleep behavior disorder and REM sleep without atonia in probable Alzheimer disease. Sleep (2006) 1.00

Disease progression in vascular cognitive impairment: cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. J Neurol Sci (2006) 0.99

The assessment of recognition memory using the Remember/Know procedure in amnestic mild cognitive impairment and probable Alzheimer's disease. Brain Cogn (2009) 0.96

Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement (2011) 0.96

Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. Dement Geriatr Cogn Disord (2009) 0.96

Inhibition impairments in Alzheimer's disease, mild cognitive impairment and healthy aging: effect of congruency proportion in a Stroop task. Neuropsychologia (2009) 0.96

The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. Can J Neurol Sci (2003) 0.92

Clinical practice guidelines for severe Alzheimer's disease. Alzheimers Dement (2007) 0.92

Recollection and familiarity in aging individuals with mild cognitive impairment and Alzheimer's disease: a literature review. Neuropsychol Rev (2014) 0.92

Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90

Task switching capacities in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychologia (2008) 0.89

Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. J Neurol Sci (2005) 0.89

Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis (2010) 0.87

Executive functions in mild cognitive impairment: emergence and breakdown of neural plasticity. Cortex (2012) 0.87

Executive function deficits in persons with mild cognitive impairment: a study with a Tower of London task. J Clin Exp Neuropsychol (2012) 0.86

Impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment. Dement Geriatr Cogn Disord (2009) 0.86

The association between depressive and cognitive symptoms in amnestic mild cognitive impairment. Int Psychogeriatr (2008) 0.86

Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. J Neuroinflammation (2014) 0.85

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement (2009) 0.85

Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients. Alzheimers Dement (2009) 0.84

White matter abnormalities and structural hippocampal disconnections in amnestic mild cognitive impairment and Alzheimer's disease. PLoS One (2013) 0.84

Longitudinal changes in functional disability in Alzheimer's disease patients. Int Psychogeriatr (2013) 0.84

Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. J Neurol Sci (2009) 0.83

Single- and multiple-domain amnestic mild cognitive impairment: two sides of the same coin? Dement Geriatr Cogn Disord (2009) 0.83

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr (2013) 0.83

An exploration of cognitive subgroups in Alzheimer's disease. J Int Neuropsychol Soc (2009) 0.82

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin (2010) 0.82

Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci (2006) 0.82

Alzheimer's disease: the pharmacological pathway. Fundam Clin Pharmacol (2003) 0.82

Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors. Neurol Res (2004) 0.82

Proposed guidelines for the participation of persons with dementia as research subjects. Perspect Biol Med (1995) 0.82

Ethical issues in Alzheimer's disease: an overview. Expert Rev Neurother (2012) 0.82

Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort. Dement Geriatr Cogn Disord (2008) 0.81

Cerebrolysin: a review of its use in dementia. Drugs Aging (2009) 0.81

Memory for gist and detail information in Alzheimer's disease and mild cognitive impairment. Neuropsychology (2006) 0.81

International price comparisons of Alzheimer's drugs: a way to close the affordability gap. Int Psychogeriatr (2009) 0.81

Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Mol Diagn Ther (2011) 0.81

Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease. CNS Drugs (2013) 0.81

Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice. Alzheimers Res Ther (2011) 0.80

The nature of episodic memory deficits in MCI with and without vascular burden. Neuropsychologia (2011) 0.80

Sertraline improves executive function in patients with vascular cognitive impairment. J Neuropsychiatry Clin Neurosci (2009) 0.80

What is certain and what is not so certain in our knowledge of Rayleigh-Taylor mixing? Philos Trans A Math Phys Eng Sci (2013) 0.80

The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson's disease dementia. Int Psychogeriatr (2012) 0.79

Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr (2010) 0.79

Canadian Alzheimer's disease caregiver survey: baby-boomer caregivers and burden of care. Int J Geriatr Psychiatry (2010) 0.79

Cerebral small-vessel disease: what lies beyond the early years? Neurology (2011) 0.79

Burden, anxiety and depression in caregivers of veterans with dementia in Beijing. Arch Gerontol Geriatr (2012) 0.79

Revised research diagnostic criteria for Alzheimer's disease. Lancet Neurol (2008) 0.79

Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry (2011) 0.79

Spotlight on cerebrolysin in dementia. CNS Drugs (2010) 0.79

Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci (2006) 0.79

Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. Biochem J (2003) 0.79

The utility of the new research diagnostic criteria for Alzheimer's disease. Int Psychogeriatr (2012) 0.79

Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies. Can J Neurol Sci (2007) 0.78

Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. Amyloid (2014) 0.78

Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ (2006) 0.78

Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease. Trials (2011) 0.78

Drugs for Alzheimer's disease and related dementias. BMJ (2005) 0.77

Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease. Int J Geriatr Psychiatry (2011) 0.77

A 10-year perspective on donepezil. Expert Opin Pharmacother (2013) 0.77

Cholinesterase inhibitors in late-stage Alzheimer's disease. Lancet Neurol (2006) 0.77

Use of memantine to treat Alzheimer's disease. CMAJ (2006) 0.76